PCT No. PCT/EP93/02832 Sec. 371 Date Apr. 12, 1995 Sec. 102(e) Date Apr. 12, 1995 PCT Filed Oct. 14, 1993 PCT Pub. No. WO94/08576 PCT Pub. Date Apr. 28, 1994This invention relates to a composition which is substantially free of the bitter taste associated with ranitidine and comprises: a) a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle;b) particles comprising ranitidine or a physiologically acceptable salt thereof incorpo...

The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

The histamine H2 antagonist ranitidine.HCl, i.e. N-[2- [[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl- N1-methyl-2-nitro-1,1-ethenediamine hydrochloride, can also exist in a novel crystalline form. This is obtained by selective crystallization of ranitidine hydrochloride.

PCT No. PCT/EP93/02763 Sec. 371 Date Apr. 11, 1995 Sec. 102(e) Date Apr. 11, 1995 PCT Filed Oct. 11, 1993 PCT Pub. No. WO94/08560 PCT Pub. Date Apr. 28, 1994The present invention provides a chewable ranitidine tablet comprising ranitidine, or a physiologically acceptable salt thereof, a chewable base selected from sucrose, glucose, lactose, maltose, or a mixture thereof, a flavouring and, optionally, an intense sweetener and a process for its preparation.

The invention relates to the use of compounds of the general formula (I) (I) wherein R1 represents a hydrogen atom or a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-(C1-4) alkyl, C3-6 alkenyl, C3-10 alkynyl, phenyl or phenyl-C1-3 alkyl group